This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ZELTIQ® Announces Criminal Judgments In Its Favor Ordered By Court In South Korea

ZELTIQ Aesthetics, Inc. (Nasdaq: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced that criminal judgments and monetary fines have been ordered by Seoul Central District Court in South Korea against two individuals for false and exaggerated advertising of a cooling device that has not been approved for fat reduction. ZELTIQ is the only company that has received approval from the Korea Food and Drug Administration (KFDA) to market and sell a device that achieves fat reduction through controlled cooling.

Criminal proceedings in South Korea were instituted against two individuals who were using Internet pages and blogs to falsely advertise that other cooling devices had the same fat reducing effect as ZELTIQ’s approved device. After a police investigation into these advertising activities, criminal proceedings were initiated. Seoul Central District Court has now imposed monetary fines and finalized criminal judgments on the counts of false and exaggerated advertising. The Korean police are also currently investigating additional advertising activities and acts of trademark infringement.

Steve Atkinson, SVP of International at ZELTIQ, commented, "ZELTIQ has invested substantial efforts to develop safe and effective devices that are approved for fat reduction and has secured regulatory approvals for those devices. ZELTIQ will vigilantly pursue persons or companies that are attempting to confuse or mislead consumers or physician-providers by inferring that any cold platform technology can do what the CoolSculpting System uniquely has proven we can safely do: reduce exercise-resistant fat non-surgically. We will not stand idly by while poseurs try to muddy our clear advantages.”

Atkinson added, “We firmly believe that the recent criminal judgments in South Korea will deter others from marketing and selling products that do not use proven technology or have the same regulatory approvals as ZELTIQ.”

For more information on ZELTIQ, visit

About ZELTIQ® Aesthetics, Inc.

ZELTIQ Aesthetics is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. The Company's first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis, without causing scar tissue or damage to the skin, nerves, or surrounding tissues. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $118.00 1.10%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs